BioMed Realty’s flagship research development at Babraham Research Campus now at 75% pre-let


27-01-2020
Interior of RxCelerate building at at the Babraham Research Campus

BioMed Realty, a Blackstone portfolio company and a leading provider of real estate solutions to the life sciences community, and RxCelerate, one of the leading out-sourced drug discovery and development platforms, have signed an agreement for RxCelerate to occupy 25,000 square feet of premium laboratory and office space in the Company’s new development at the Babraham Research Campus.

“RxCelerate has experienced rapid expansion over the last five years, adding significant new services to our out-sourced drug R&D platform. Our team, now in excess of 50, has outgrown our existing space, across several different buildings on the Babraham Research Campus, and therefore the opportunity to move our Cambridge UK headquarters into such a prestigious building on the same campus came at the perfect time for our business,” said Dr Jill Reckless, CEO, RxCelerate Group.

David Grainger, Executive Chairman, RxCelerate Group, added “Babraham Research Campus has always been a fantastic place to start new bioscience companies, and it’s great to see this new development providing such high-quality space for those companies to expand without leaving their base. We are very excited to commence the next phase of our growth in our new home.”

In October 2017, BioMed Realty and the Babraham Research Campus launched a partnership, creating 100,000 square feet of research space for growing bioscience-based companies seeking to scale up their operations. BioMed@Babraham encompasses two adjacent buildings that will provide high quality research space for growing bioscience-based companies. Set to open as early as April 2020, the buildings are now 75% pre-let, highlighting the booming life science community of academia, research institutions and industry.

“BioMed Realty has been a part of Cambridge’s vibrant life science community since our acquisition of Granta Park in 2012 and we are very excited to continue the letting expansions at BioMed@Babraham with RxCelerate,” said Matt Smith, Director, UK Market of BioMed Realty. “The Babraham Research Campus is considered to be the UK's leading campus to support early-stage bioscience enterprise, and we’re thrilled to welcome our expanding group of tenants to BioMed@Babraham.”

As life sciences in the UK continues to thrive – the sector currently contributes over £70 billion to the UK economy and provides jobs for over 240,000 people across the country - BioMed@Babraham offers a unique space for the Cambridge life science innovation district to call home.


About BioMed Realty

Founded in 2004, and a Blackstone portfolio company since 2016, BioMed Realty owns, operates and develops high quality life science real estate comprising 13.6 million square feet, including 2.6 million square feet of Class A properties in active development to meet the growing demand of the life science industry. BioMed Realty’s portfolio is located in the leading innovation markets throughout the United States and United Kingdom, led by Boston-Cambridge, San Francisco, San Diego, Seattle, New York and Cambridge, U.K. With over 200 tenant partners, BioMed Realty provides real estate solutions for global enterprises, established biotechnology and innovation companies, leading universities and premier research institutions. To learn more about BioMed Realty, visit biomedrealty.com, and please follow us on Twitter @biomedrealty.

About RxCelerate

RxCelerate is an outsourced drug discovery and development company, founded in Cambridge, U.K., in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of a wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches. For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate).

About the Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support U.K. bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute.

For more information please visit: www.babraham.com

 

BioMed Realty has been part of Cambridge's world-class life science community since the acquisition of Granta Park in 2012. Granta Park is a 477,230 square foot business estate in one of the most reconised areas for science success globally and is home to leading companies, including Sosei Heptares, Astrazeneca, Illumina, PPD Global, and One Nucleus.

BioMed Realty